Publications by authors named "E Bastiaannet"
Introduction: Age and comorbidity are considered the strongest predictors for adverse events after colorectal cancer (CRC) surgery. We aimed to study the interaction of age and comorbidity and to gain better insight in options to improve care for the growing group of older patients.
Materials And Methods: We included all patients ≥70 years undergoing elective surgery for non-metastatic CRC between 2011 and 2019 in the Netherlands.
Purpose Of Review: What are the prevalence, incidence and mortality rates of cancer among individuals aged 60 or older on a national, regional, and global scale? What factors affect differences in cancer survival between older and younger adults?
Recent Findings: The epidemiological literature on cancer in older adults, particularly in low- and middle-income countries (LMICs) and that focusing on the oldest adults, is expanding. These studies consistently show increasing global cancer incidence rates in older populations. Recent research also highlights a widening survival gap between middle-aged and older adults, with the stage at diagnosis being the primary driver.
Article Synopsis
- The review aimed to analyze the use of frailty assessments in recent studies focused on older women (65+) with breast cancer, specifically looking at their impact on survival and mortality outcomes from 2017 to 2022.
- A systematic search of databases like MEDLINE, EMBASE, and Cochrane Library identified 130 relevant observational studies out of nearly 10,000 screened, but only 11 of these (8.5%) incorporated frailty assessments.
- The findings revealed significant variability in how frailty is defined and classified across studies, with key assessments like the Balducci score and Geriatric 8 tool being used, and quantified frailty classifications showing that 18% to 29% were considered pre
Introduction: There have been several developments in the treatment of HER2-overexpressing metastatic breast cancer. However, pivotal trials mainly included younger and healthier patients, resulting in a lack of information about the benefits and harms of treatment for most older patients. The aim of this study was to provide an overview of the differences in treatment allocation and survival outcomes over time between younger and older patients with HER2-overexpressing metastatic breast cancer.
View Article and Find Full Text PDF